SALT LAKE CITY, May 12, 2020 /PRNewswire/ -- Co-Diagnostics,
Inc. (Nasdaq: CODX), a molecular diagnostics company
with a unique, patented platform for the development of molecular
diagnostic tests, announced today that it will release its first
quarter 2020 earnings on May 14, 2020
after the close of trading on that day, and will hold an earnings
call at 4:30 pm EDT. The call is
expected to consist of prepared remarks by Company CEO Dwight Egan, and include mid-quarter guidance
for the second quarter 2020. Analysts providing coverage for
Co-Diagnostics will also be invited participate in a question and
answer session.
U.S. callers may dial toll free at 1-877-309-2073. International
callers can access the call by dialing +1-646-749-3129. The access
code to join the call is: 531-241-589. The call will be recorded
and later made available on the Company's website.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company's balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-q1-2020-earnings-release-date-and-earnings-call-301058070.html
SOURCE Co-Diagnostics